Sodium-Glucose Cotransporter 2 Inhibitors for Metabolic Dysfunction-Associated Steatohepatitis

Abstract

MASH denotes metabolic dysfunction-associated steatohepatitis. MASH improvement was defined as a decrease in the non-alcoholic fatty liver disease activity score (NAS) of ≥ 2 points or NAS ≤ 3 at week 48 after treatment, with no worsening of fibrosis (i.e., no increase in fibrosis stage). MASH resolution was defined as a hepatocellular ballooning score of 0 and a lobular inflammation score of 0 or 1 at week 48, with no worsening of fibrosis. Fibrosis improvement was defined as a reduction in fibrosis of ≥ 1 stage at week 48, with no worsening of MASH (i.e., no increase in steatosis, ballooning, or inflammation scores).